Period,symbol,NAV,sharesOutstanding,researchDevelopment,effectOfAccountingCharges,incomeBeforeTax,minorityInterest,netIncome,sellingGeneralAdministrative,grossProfit,ebit,operatingIncome,otherOperatingExpenses,interestExpense,extraordinaryItems,nonRecurring,otherItems,incomeTaxExpense,totalRevenue,totalOperatingExpenses,costOfRevenue,totalOtherIncomeExpenseNet,discontinuedOperations,netIncomeFromContinuingOps,netIncomeApplicableToCommonShares,intangibleAssets,capitalSurplus,totalLiab,totalStockholderEquity,otherCurrentLiab,totalAssets,commonStock,otherCurrentAssets,retainedEarnings,otherLiab,treasuryStock,otherAssets,cash,totalCurrentLiabilities,shortLongTermDebt,otherStockholderEquity,propertyPlantEquipment,totalCurrentAssets,longTermDebt,accountsPayable,netReceivables,investments,changeToLiabilities,totalCashflowsFromInvestingActivities,netBorrowings,totalCashFromFinancingActivities,changeToOperatingActivities,issuanceOfStock,changeInCash,effectOfExchangeRate,totalCashFromOperatingActivities,depreciation,changeToAccountReceivables,changeToNetincome,capitalExpenditures,otherCashflowsFromFinancingActivities,repurchaseOfStock,otherCashflowsFromInvestingActivities,changeToInventory,WC,language,region,quoteType,triggerable,quoteSourceName,exchange,currency,regularMarketPrice,regularMarketTime,regularMarketChange,regularMarketOpen,regularMarketDayHigh,regularMarketDayLow,regularMarketVolume,regularMarketPreviousClose,bid,ask,bidSize,askSize,messageBoardId,fullExchangeName,longName,financialCurrency,averageDailyVolume3Month,averageDailyVolume10Day,fiftyTwoWeekLowChange,fiftyTwoWeekLowChangePercent,fiftyTwoWeekRange,fiftyTwoWeekHighChange,fiftyTwoWeekHighChangePercent,fiftyTwoWeekLow,fiftyTwoWeekHigh,marketState,market,shortName,exchangeDataDelayedBy,esgPopulated,tradeable,priceHint,regularMarketChangePercent,regularMarketDayRange,epsTrailingTwelveMonths,epsForward,epsCurrentYear,priceEpsCurrentYear,bookValue,fiftyDayAverage,fiftyDayAverageChange,fiftyDayAverageChangePercent,twoHundredDayAverage,twoHundredDayAverageChange,twoHundredDayAverageChangePercent,marketCap,forwardPE,priceToBook,sourceInterval,exchangeTimezoneName,exchangeTimezoneShortName,gmtOffSetMilliseconds,Beta (5Y Monthly),52-Week Change 3,S&P500 52-Week Change 3,52 Week High 3,52 Week Low 3,50-Day Moving Average 3,200-Day Moving Average 3,Avg Vol (3 month) 3,Avg Vol (10 day) 3,Shares Outstanding 5,Implied Shares Outstanding 6,Float,% Held by Insiders 1,% Held by Institutions 1,"Shares Short (Jul 29, 2021) 4","Short Ratio (Jul 29, 2021) 4","Short % of Float (Jul 29, 2021) 4","Short % of Shares Outstanding (Jul 29, 2021) 4","Shares Short (prior month Jun 29, 2021) 4",Forward Annual Dividend Rate 4,Forward Annual Dividend Yield 4,Trailing Annual Dividend Rate 3,Trailing Annual Dividend Yield 3,5 Year Average Dividend Yield 4,Payout Ratio 4,Dividend Date 3,Ex-Dividend Date 4,Last Split Factor 2,Last Split Date 3,Fiscal Year Ends,Most Recent Quarter (mrq),Profit Margin,Operating Margin (ttm),Return on Assets (ttm),Return on Equity (ttm),Revenue (ttm),Revenue Per Share (ttm),Quarterly Revenue Growth (yoy),Gross Profit (ttm),EBITDA,Net Income Avi to Common (ttm),Diluted EPS (ttm),Quarterly Earnings Growth (yoy),Total Cash (mrq),Total Cash Per Share (mrq),Total Debt (mrq),Total Debt/Equity (mrq),Current Ratio (mrq),Book Value Per Share (mrq),Operating Cash Flow (ttm),Levered Free Cash Flow (ttm),index,zip,sector,fullTimeEmployees,compensationRisk,auditRisk,longBusinessSummary,city,phone,shareHolderRightsRisk,compensationAsOfEpochDate,governanceEpochDate,boardRisk,country,website,maxAge,overallRisk,address1,fax,industry
t0,DBVT,142994000.0,109791000,20179000,,-31088000,,-30654000,9467000,-1488000,-31134000,-31134000,,,,,,-434000,-1488000,29646000,0,46000,,-30654000,-30654000,25000.0,357530000.0,57565000.0,143019000.0,12077000.0,200584000.0,6529000.0,13108000.0,-220823000.0,9535000.0,-217000.0,32758000.0,125484000.0,38698000.0,710000.0,649000.0,29209000.0,138592000.0,177000.0,16335000.0,,1000.0,-598000.0,172000.0,-181000.0,631000.0,-7020000.0,812000.0,-26975000.0,2521000.0,-30299000.0,7136000.0,74000.0,763000.0,171000.0,,,,,99894000.0,en-US,US,EQUITY,True,Nasdaq Real Time Price,NMS,USD,5.63,1630503481,-0.28999996,5.63,5.64,5.63,8688,5.92,5.59,5.62,8,8,finmb_7406282,NasdaqGS,DBV Technologies S.A.,USD,60648,36583,4.28,3.1703706,1.35 - 7.38,-1.75,-0.23712736,1.35,7.38,REGULAR,us_market,DBV Technologies S.A.,0,False,False,2,-4.898648,5.63 - 5.64,-1.475,-2.58,-1.83,-3.0765028,1.874,5.077778,0.55222225,0.10875274,5.6114855,0.018514633,0.0032994174,640755968,-2.1821706,3.0042691,15,America/New_York,EDT,-14400000,2.22,,,7.38,1.35,5.08,5.61,60.65k,36.58k,109.79M,,61.24M,0.06%,33.86%,1.67M,29.24,,1.52%,1.77M,,,,,,0.00%,,,,,"Dec 30, 2020","Jun 29, 2021",0.00%,"-2,919.55%",-29.85%,-66.03%,4.4M,0.04,,11.28M,-116.91M,-130.54M,-1.48,,125.48M,1.14,12.8M,8.95,3.58,1.87,-142.26M,-88.66M,Value,92120,Healthcare,97,10,7,"DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies in 4 to 11 years of age children, adolescents, and adults. The company is also developing Viaskin Milk that is in Phase I/II clinical trial for the treatment of Immunoglobulin E (IgE) mediated cow's milk protein allergy (CMPA) and milk-induced eosinophilic esophagitis; Viaskin Egg, a pre-clinical stage product for the treatment of hen's egg allergy; and booster vaccine for Bordetella pertussis. Its other earlier stage research programs include a vaccine for the respiratory syncytial virus, as well as treatments for Crohn's disease, celiac disease, and type I diabetes. The company has a collaboration with NestlÃ© Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was founded in 2002 and is headquartered in Montrouge, France.",Montrouge,33 1 55 42 78 78,1,1609372800,1625097600,9,France,http://www.dbv-technologies.com,86400,9,177-181 Avenue Pierre Brossolette,33 1 43 26 10 83,Biotechnology
t-1,DBVT,169144000.0,109791000,22164000,,-29419000,,-29449000,10412000,2941000,-29635000,-29635000,,,,,,30000,2941000,32576000,0,216000,,-29449000,-29449000,32000.0,1153516000.0,52229000.0,169176000.0,8395000.0,221405000.0,6519000.0,7350000.0,-987992000.0,3515000.0,-2867000.0,30870000.0,152459000.0,38831000.0,701000.0,-2186000.0,30694000.0,159809000.0,350000.0,17176000.0,,-1000.0,-2567000.0,-185000.0,-164000.0,440000.0,-8750000.0,620000.0,-43893000.0,-7944000.0,-36204000.0,1483000.0,2101000.0,978000.0,-184000.0,-16000.0,,,,120978000.0,en-US,US,EQUITY,True,Nasdaq Real Time Price,NMS,USD,5.63,1630503481,-0.28999996,5.63,5.64,5.63,8688,5.92,5.59,5.62,8,8,finmb_7406282,NasdaqGS,DBV Technologies S.A.,USD,60648,36583,4.28,3.1703706,1.35 - 7.38,-1.75,-0.23712736,1.35,7.38,REGULAR,us_market,DBV Technologies S.A.,0,False,False,2,-4.898648,5.63 - 5.64,-1.475,-2.58,-1.83,-3.0765028,1.874,5.077778,0.55222225,0.10875274,5.6114855,0.018514633,0.0032994174,640755968,-2.1821706,3.0042691,15,America/New_York,EDT,-14400000,2.22,,,7.38,1.35,5.08,5.61,60.65k,36.58k,109.79M,,61.24M,0.06%,33.86%,1.67M,29.24,,1.52%,1.77M,,,,,,0.00%,,,,,"Dec 30, 2020","Jun 29, 2021",0.00%,"-2,919.55%",-29.85%,-66.03%,4.4M,0.04,,11.28M,-116.91M,-130.54M,-1.48,,125.48M,1.14,12.8M,8.95,3.58,1.87,-142.26M,-88.66M,Value,92120,Healthcare,97,10,7,"DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies in 4 to 11 years of age children, adolescents, and adults. The company is also developing Viaskin Milk that is in Phase I/II clinical trial for the treatment of Immunoglobulin E (IgE) mediated cow's milk protein allergy (CMPA) and milk-induced eosinophilic esophagitis; Viaskin Egg, a pre-clinical stage product for the treatment of hen's egg allergy; and booster vaccine for Bordetella pertussis. Its other earlier stage research programs include a vaccine for the respiratory syncytial virus, as well as treatments for Crohn's disease, celiac disease, and type I diabetes. The company has a collaboration with NestlÃ© Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was founded in 2002 and is headquartered in Montrouge, France.",Montrouge,33 1 55 42 78 78,1,1609372800,1625097600,9,France,http://www.dbv-technologies.com,86400,9,177-181 Avenue Pierre Brossolette,33 1 43 26 10 83,Biotechnology
t-2,DBVT,205450000.0,109791000,19566682,,-26852225,,-26845390,8372476,2419040,-26924399,-26924399,1404281.0,-119266.0,,,,-6835,2419040,29343439,0,72174,,-26845390,-26845390,41000.0,1152042000.0,66755000.0,205491000.0,11282000.0,272247000.0,6518000.0,1000.0,-958543000.0,3003000.0,5474000.0,29935000.0,196352000.0,52713000.0,724000.0,6643000.0,34896000.0,207375000.0,543000.0,20338000.0,7860000.0,-48442.0,-3479226.0,-628219.0,830151.0,-7327529.0,1759012.0,620000.0,-31376271.0,10799379.0,-34220014.0,-781217.0,-1035000.0,-5796800.0,-570893.0,278524.0,-8436204.0,-500.0,1958607.0,154662000.0,en-US,US,EQUITY,True,Nasdaq Real Time Price,NMS,USD,5.63,1630503481,-0.28999996,5.63,5.64,5.63,8688,5.92,5.59,5.62,8,8,finmb_7406282,NasdaqGS,DBV Technologies S.A.,USD,60648,36583,4.28,3.1703706,1.35 - 7.38,-1.75,-0.23712736,1.35,7.38,REGULAR,us_market,DBV Technologies S.A.,0,False,False,2,-4.898648,5.63 - 5.64,-1.475,-2.58,-1.83,-3.0765028,1.874,5.077778,0.55222225,0.10875274,5.6114855,0.018514633,0.0032994174,640755968,-2.1821706,3.0042691,15,America/New_York,EDT,-14400000,2.22,,,7.38,1.35,5.08,5.61,60.65k,36.58k,109.79M,,61.24M,0.06%,33.86%,1.67M,29.24,,1.52%,1.77M,,,,,,0.00%,,,,,"Dec 30, 2020","Jun 29, 2021",0.00%,"-2,919.55%",-29.85%,-66.03%,4.4M,0.04,,11.28M,-116.91M,-130.54M,-1.48,,125.48M,1.14,12.8M,8.95,3.58,1.87,-142.26M,-88.66M,Value,92120,Healthcare,97,10,7,"DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies in 4 to 11 years of age children, adolescents, and adults. The company is also developing Viaskin Milk that is in Phase I/II clinical trial for the treatment of Immunoglobulin E (IgE) mediated cow's milk protein allergy (CMPA) and milk-induced eosinophilic esophagitis; Viaskin Egg, a pre-clinical stage product for the treatment of hen's egg allergy; and booster vaccine for Bordetella pertussis. Its other earlier stage research programs include a vaccine for the respiratory syncytial virus, as well as treatments for Crohn's disease, celiac disease, and type I diabetes. The company has a collaboration with NestlÃ© Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was founded in 2002 and is headquartered in Montrouge, France.",Montrouge,33 1 55 42 78 78,1,1609372800,1625097600,9,France,http://www.dbv-technologies.com,86400,9,177-181 Avenue Pierre Brossolette,33 1 43 26 10 83,Biotechnology
t-3,DBVT,205450000.0,109791000,20737851,,-28971673,,-28964912,9016997,2547934,-28554965,-28554965,1348051.0,-114490.0,,,,-6761,2547934,31102899,0,-416709,,-28964912,-28964912,41000.0,1152042000.0,66755000.0,205491000.0,11282000.0,272247000.0,6518000.0,1000.0,-958543000.0,3003000.0,5474000.0,29935000.0,196352000.0,52713000.0,724000.0,6643000.0,34896000.0,207375000.0,543000.0,20338000.0,7860000.0,-48564.0,-3441658.0,-660424.0,790844.0,-4039997.0,1472790.0,620000.0,-30057888.0,10807853.0,-36165407.0,-399726.0,-1035000.0,-5723671.0,-602731.0,266671.0,-5097512.0,-500.0,1926769.0,154662000.0,en-US,US,EQUITY,True,Nasdaq Real Time Price,NMS,USD,5.63,1630503481,-0.28999996,5.63,5.64,5.63,8688,5.92,5.59,5.62,8,8,finmb_7406282,NasdaqGS,DBV Technologies S.A.,USD,60648,36583,4.28,3.1703706,1.35 - 7.38,-1.75,-0.23712736,1.35,7.38,REGULAR,us_market,DBV Technologies S.A.,0,False,False,2,-4.898648,5.63 - 5.64,-1.475,-2.58,-1.83,-3.0765028,1.874,5.077778,0.55222225,0.10875274,5.6114855,0.018514633,0.0032994174,640755968,-2.1821706,3.0042691,15,America/New_York,EDT,-14400000,2.22,,,7.38,1.35,5.08,5.61,60.65k,36.58k,109.79M,,61.24M,0.06%,33.86%,1.67M,29.24,,1.52%,1.77M,,,,,,0.00%,,,,,"Dec 30, 2020","Jun 29, 2021",0.00%,"-2,919.55%",-29.85%,-66.03%,4.4M,0.04,,11.28M,-116.91M,-130.54M,-1.48,,125.48M,1.14,12.8M,8.95,3.58,1.87,-142.26M,-88.66M,Value,92120,Healthcare,97,10,7,"DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies in 4 to 11 years of age children, adolescents, and adults. The company is also developing Viaskin Milk that is in Phase I/II clinical trial for the treatment of Immunoglobulin E (IgE) mediated cow's milk protein allergy (CMPA) and milk-induced eosinophilic esophagitis; Viaskin Egg, a pre-clinical stage product for the treatment of hen's egg allergy; and booster vaccine for Bordetella pertussis. Its other earlier stage research programs include a vaccine for the respiratory syncytial virus, as well as treatments for Crohn's disease, celiac disease, and type I diabetes. The company has a collaboration with NestlÃ© Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was founded in 2002 and is headquartered in Montrouge, France.",Montrouge,33 1 55 42 78 78,1,1609372800,1625097600,9,France,http://www.dbv-technologies.com,86400,9,177-181 Avenue Pierre Brossolette,33 1 43 26 10 83,Biotechnology
